Published in J Neural Transm (Vienna) on June 05, 2008
Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther (2011) 1.71
The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav (2011) 1.29
A critical review of magnetic resonance spectroscopy studies of obsessive-compulsive disorder. Biol Psychiatry (2012) 1.07
Investigation of cortical glutamate-glutamine and γ-aminobutyric acid in obsessive-compulsive disorder by proton magnetic resonance spectroscopy. Neuropsychopharmacology (2012) 1.04
Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment. Adv Med (2014) 0.97
Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors. Front Pharmacol (2013) 0.97
Relevance of orbitofrontal neurochemistry for the outcome of cognitive-behavioural therapy in patients with obsessive-compulsive disorder. Eur Arch Psychiatry Clin Neurosci (2012) 0.87
Response inhibition and interference control in obsessive-compulsive spectrum disorders. Front Hum Neurosci (2014) 0.85
In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept. Psychiatry Res (2015) 0.82
In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl) (2013) 0.82
An Examination of Rostral Anterior Cingulate Cortex Function and Neurochemistry in Obsessive-Compulsive Disorder. Neuropsychopharmacology (2015) 0.82
Isoforms of the neuronal glutamate transporter gene, SLC1A1/EAAC1, negatively modulate glutamate uptake: relevance to obsessive-compulsive disorder. Transl Psychiatry (2013) 0.81
Effects of intensive cognitive-behavioral therapy on cingulate neurochemistry in obsessive-compulsive disorder. J Psychiatr Res (2013) 0.81
The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder. Psychopharmacology (Berl) (2010) 0.80
Reduction of N-acetylaspartate in the medial prefrontal cortex correlated with symptom severity in obsessive-compulsive disorder: meta-analyses of (1)H-MRS studies. Transl Psychiatry (2012) 0.79
Degraded water suppression in small volume ¹H MRS due to localised shimming. MAGMA (2011) 0.79
Brain functional connectivity during induced sadness in patients with obsessive-compulsive disorder. J Psychiatry Neurosci (2012) 0.78
OCD candidate gene SLC1A1/EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior. Proc Natl Acad Sci U S A (2017) 0.77
Altered intrinsic insular activity predicts symptom severity in unmedicated obsessive-compulsive disorder patients: a resting state functional magnetic resonance imaging study. BMC Psychiatry (2016) 0.75
Treatment Efficacy of Combined Sertraline and Guanfacine in Comorbid Obsessive-Compulsive Disorder and Attention Deficit/Hyperactivity Disorder: Two Case Studies. J Dev Behav Pediatr (2016) 0.75
From Thought to Action: How the Interplay Between Neuroscience and Phenomenology Changed Our Understanding of Obsessive-Compulsive Disorder. Front Psychol (2015) 0.75
Assessment of glutamate in striatal subregions in obsessive-compulsive disorder with proton magnetic resonance spectroscopy. Psychiatry Res (2015) 0.75
Neuroimaging Studies in Obsessive Compulsive Disorder: A Narrative Review. Indian J Psychol Med (2016) 0.75
Management of obsessive-compulsive disorder comorbid with bipolar disorder. Indian J Psychiatry (2017) 0.75
Glutamate in Pediatric Obsessive-Compulsive Disorder and Response to Cognitive-Behavioral Therapy: Randomized Clinical Trial. Neuropsychopharmacology (2017) 0.75
The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry (1989) 16.61
Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med (1993) 15.51
Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry (1992) 2.31
The thalamic reticular nucleus: structure, function and concept. Brain Res Brain Res Rev (2004) 1.92
Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry Suppl (1998) 1.92
In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function. Annu Rev Physiol (2002) 1.79
Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder. Arch Gen Psychiatry (1996) 1.77
An experiment of nature: brain anatomy parallels cognition and behavior in Williams syndrome. J Neurosci (2004) 1.76
A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Res (2004) 1.70
Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Arch Gen Psychiatry (1989) 1.56
White matter abnormalities in obsessive-compulsive disorder: a diffusion tensor imaging study. Arch Gen Psychiatry (2005) 1.49
Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry (2000) 1.44
Regional xenon 133 cerebral blood flow and cerebral technetium 99m HMPAO uptake in unmedicated patients with obsessive-compulsive disorder and matched normal control subjects. Determination by high-resolution single-photon emission computed tomography. Arch Gen Psychiatry (1992) 1.26
Cerebral glucose metabolic rates in obsessive compulsive disorder. Neuropsychopharmacology (1989) 1.23
A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety. Psychiatry Res (2006) 1.12
Neural correlates of clinical symptoms and cognitive dysfunctions in obsessive-compulsive disorder. Psychiatry Res (2003) 1.11
Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Patients treated with clomipramine. Arch Gen Psychiatry (1990) 1.07
Parieto-occipital grey matter abnormalities in children with Williams syndrome. Neuroimage (2005) 1.01
A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders--focus on magnetic resonance spectroscopy (MRS) studies. Hum Psychopharmacol (2005) 1.01
Projection from the external pallidum to the reticular thalamic nucleus in the squirrel monkey. Brain Res (1991) 0.94
Selective cognitive deficits in obsessive-compulsive disorder compared to panic disorder with agoraphobia. Acta Psychiatr Scand (2005) 0.93
The caudate nucleus in obsessive-compulsive disorder. Reduced metabolism following treatment with paroxetine: a PET study. Int J Neuropsychopharmacol (2002) 0.89
Treatment of obsessive-compulsive disorder by psychosurgery. Acta Psychiatr Scand (1993) 0.88
Evidence for coupling between glucose metabolism and glutamate cycling using FDG PET and 1H magnetic resonance spectroscopy in patients with epilepsy. J Cereb Blood Flow Metab (2000) 0.87
On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry (2001) 0.86
Increased MEG activation in OCD reflects a compensatory mechanism specific to the phase of a visual working memory task. Neuroimage (2004) 0.85
Neuroimaging studies of obsessive compulsive disorder. Psychiatr Clin North Am (1992) 0.83
Regional 133xenon cerebral blood flow and cerebral 99mTc-HMPAO uptake in patients with obsessive-compulsive disorder before and during treatment. Biol Psychiatry (1995) 0.83
Obsessive-compulsive disorder and ventromedial frontal lesions: clinical and neuropsychological findings. Am J Psychiatry (1998) 0.80
Neuropsychological performance and regional cerebral blood flow in obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2003) 0.80
MR spectroscopy: a powerful tool for investigating brain function and neurological diseases. Neurochem Res (2000) 0.77
Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue. J Neural Transm Gen Sect (1994) 0.76
On the mode of action of six putative dopamine receptor agonists on suppression of exploratory behaviour in rats. Psychopharmacology (Berl) (1987) 0.76
Basal ganglia neuropharmacology and obsessive-compulsive disorder: the obsessive-compulsive disorder hypothesis of basal ganglia dysfunction. Psychopharmacol Bull (1988) 0.75
Different behavioural patterns induced by the dopamine agonist apomorphine analysed by multivariate statistics. Pharmacol Biochem Behav (1986) 0.75
Vertebroplasty: cement leakage into the disc increases the risk of new fracture of adjacent vertebral body. AJNR Am J Neuroradiol (2004) 2.91
Stunning of iodide transport by (131)I irradiation in cultured thyroid epithelial cells. J Nucl Med (2002) 2.16
The prevalence of neck pain: a population-based study from northern Sweden. Acta Orthop Scand (2002) 1.54
Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res (2007) 1.53
Accuracy and reproducibility of manual and semiautomated quantification of MS lesions by MRI. J Magn Reson Imaging (2003) 1.45
Quantification of accuracy and precision of multi-center DTI measurements: a diffusion phantom and human brain study. Neuroimage (2011) 1.30
Intersubject variability in the anterior extent of the optic radiation assessed by tractography. Epilepsy Res (2007) 1.24
Diffusion-weighted imaging for differentiating benign from malignant skull lesions and correlation with cell density. AJR Am J Roentgenol (2012) 1.24
Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation. Arterioscler Thromb Vasc Biol (2012) 1.17
Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry (2003) 1.15
The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov (2009) 1.12
Functional impairment in clinical samples of Norwegian and Swedish children and adolescents with obsessive-compulsive disorder. Eur Child Adolesc Psychiatry (2005) 1.10
(+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2005) 1.10
Autologous chondrocyte implantation in cartilage lesions of the knee: long-term evaluation with magnetic resonance imaging and delayed gadolinium-enhanced magnetic resonance imaging technique. Am J Sports Med (2010) 1.09
Renal function affects absorbed dose to the kidneys and haematological toxicity during ¹⁷⁷Lu-DOTATATE treatment. Eur J Nucl Med Mol Imaging (2015) 1.03
MR diffusion tensor and perfusion-weighted imaging in preoperative grading of supratentorial nonenhancing gliomas. Neuro Oncol (2011) 1.03
Glial-neuronal interactions are impaired in the schizophrenia model of repeated MK801 exposure. Neuropsychopharmacology (2005) 1.00
Quantitative analysis of tumor growth rate and changes in tumor marker level: specific growth rate versus doubling time. Acta Oncol (2009) 1.00
Evaluation of measurement uncertainties in human diffusion tensor imaging (DTI)-derived parameters and optimization of clinical DTI protocols with a wild bootstrap analysis. J Magn Reson Imaging (2009) 1.00
A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues Clin Neurosci (2006) 0.99
Effects of internal low-dose irradiation from 131I on gene expression in normal tissues in Balb/c mice. EJNMMI Res (2011) 0.99
[177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney. World J Surg (2010) 0.98
Transcriptional response of BALB/c mouse thyroids following in vivo astatine-211 exposure reveals distinct gene expression profiles. EJNMMI Res (2012) 0.98
Radiation-induced thyroid stunning: differential effects of (123)I, (131)I, (99m)Tc, and (211)At on iodide transport and NIS mRNA expression in cultured thyroid cells. J Nucl Med (2009) 0.96
Biodistribution of free 211At and 125I- in nude mice bearing tumors derived from anaplastic thyroid carcinoma cell lines. Cancer Biother Radiopharm (2006) 0.95
Additive effect of the AZGP1, PIP, S100A8 and UBE2C molecular biomarkers improves outcome prediction in breast carcinoma. Int J Cancer (2013) 0.94
Longitudinal study of the diffusion tensor imaging properties of the corpus callosum in acute and chronic diffuse axonal injury. Brain Inj (2011) 0.94
Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. J Neural Transm (Vienna) (2008) 0.94
Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque. Stroke (2012) 0.94
Tumour size measurement in a mouse model using high resolution MRI. BMC Med Imaging (2012) 0.93
Patterns of white matter injury in HIV infection after partial immune reconstitution: a DTI tract-based spatial statistics study. J Neurovirol (2012) 0.92
Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy. EJNMMI Res (2012) 0.92
Down-regulation of the sodium/iodide symporter explains 131I-induced thyroid stunning. Cancer Res (2007) 0.91
Comparative analysis of transcriptional gene regulation indicates similar physiologic response in mouse tissues at low absorbed doses from intravenously administered 211At. J Nucl Med (2013) 0.91
Diurnal cortisol levels and cortisol response in youths with obsessive-compulsive disorder. Neuropsychobiology (2008) 0.91
The monoamine stabilizer (-)-OSU6162 attenuates voluntary ethanol intake and ethanol-induced dopamine output in nucleus accumbens. Biol Psychiatry (2012) 0.90
Golf courses and wetland fauna. Ecol Appl (2009) 0.89
Reduced frontotemporal perfusion in psychopathic personality. Psychiatry Res (2002) 0.89
Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model. J Nucl Med (2004) 0.89
Biodistribution and dosimetry of free 211At, 125I- and 131I- in rats. Cancer Biother Radiopharm (2013) 0.89
Nephrotoxicity profiles and threshold dose values for [177Lu]-DOTATATE in nude mice. Nucl Med Biol (2012) 0.87
A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy. Brain (2012) 0.87
Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas? Ann N Y Acad Sci (2006) 0.87
Interhemispheric transfer in high-functioning children and adolescents with autism spectrum disorders: a controlled pilot study. Dev Med Child Neurol (2004) 0.87
Reduced iodide transport (stunning) and DNA synthesis in thyrocytes exposed to low absorbed doses from 131I in vitro. J Nucl Med (2007) 0.87
Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul Pept (2004) 0.87
Different stages of white matter changes in the original HDLS family revealed by advanced MRI techniques. J Neuroimaging (2013) 0.86
The Nordic long-term OCD treatment study (NordLOTS): rationale, design, and methods. Child Adolesc Psychiatry Ment Health (2013) 0.86
SPatial REgression Analysis of Diffusion tensor imaging (SPREAD) for longitudinal progression of neurodegenerative disease in individual subjects. Magn Reson Imaging (2013) 0.85
Altered brain microstructure assessed by diffusion tensor imaging in patients with diabetes and gastrointestinal symptoms. Diabetes Care (2012) 0.85
Nicotine treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2004) 0.84
Model of metastatic growth valuable for radionuclide therapy. Med Phys (2003) 0.84
Microdosimetric analysis of 211At in thyroid models for man, rat and mouse. EJNMMI Res (2012) 0.84
Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution. Med Phys (2006) 0.84
Advanced MR diffusion tensor imaging and perfusion weighted imaging of intramedullary tumors and tumor like lesions in the cervicomedullary junction region and the cervical spinal cord. J Neurooncol (2013) 0.84
Adaptive properties and heterogeneity of dopamine D(2) receptors - pharmacological implications. Brain Res Rev (2007) 0.83
Hippocampal volumes in patients exposed to low-dose radiation to the basal brain. A case-control study in long-term survivors from cancer in the head and neck region. Radiat Oncol (2012) 0.83
Quality of life in children with OCD before and after treatment. Eur Child Adolesc Psychiatry (2014) 0.83
New medical strategies for midgut carcinoids. Anticancer Agents Med Chem (2010) 0.83
The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition. Prog Neuropsychopharmacol Biol Psychiatry (2004) 0.83
N-Acetyl peak in MR spectra of intracranial metastatic mucinous adenocarcinomas. Magn Reson Imaging (2010) 0.83
Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production. J Nucl Med (2006) 0.83
The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.82
Translation of dosimetric results of preclinical radionuclide therapy to clinical situations: influence of photon irradiation. Cancer Biother Radiopharm (2007) 0.82
A new method to estimate parameters of the growth model for metastatic tumours. Theor Biol Med Model (2013) 0.82
Tumour control probability (TCP) for non-uniform activity distribution in radionuclide therapy. Phys Med Biol (2008) 0.82
Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro. Nucl Med Biol (2006) 0.82
Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model. Cancer Biother Radiopharm (2005) 0.82
Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1. Cancer Biother Radiopharm (2008) 0.81
Exploring the usability of a videophone mock-up for persons with dementia and their significant others. BMC Geriatr (2014) 0.81
I. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors. J Neural Transm (Vienna) (2011) 0.81
Modifying a standard method allows simultaneous extraction of RNA and protein, enabling detection of enzymes in the rat retina with low expressions and protein levels. Metabolism (2006) 0.81
Therapy with radiopharmaceuticals. Acta Oncol (2002) 0.81
Malignant pheochromocytoma in a population-based study: survival and clinical results. Ann N Y Acad Sci (2006) 0.81
Different corticostriatal patterns of L-DOPA utilization in patients with untreated schizophrenia and patients treated with classical antipsychotics or clozapine. Scand J Psychol (2003) 0.81
Expression of antioxidant enzymes in rat retinal ischemia followed by reperfusion. Metabolism (2006) 0.81
MR perfusion-weighted imaging may help in differentiating between nonenhancing gliomas and nonneoplastic lesions in the cervicomedullary junction. J Magn Reson Imaging (2011) 0.80
Progressive decline in fractional anisotropy on serial DTI examinations of the corpus callosum: a putative marker of disease activity and progression in SPMS. Neuroradiology (2011) 0.80
Rehabilitation problems after acute disseminated encephalomyelitis: four cases. J Rehabil Med (2003) 0.80
Importance of vesicle proteins in the diagnosis and treatment of neuroendocrine tumors. Ann N Y Acad Sci (2004) 0.80
Continued cognitive-behavior therapy versus sertraline for children and adolescents with obsessive-compulsive disorder that were non-responders to cognitive-behavior therapy: a randomized controlled trial. Eur Child Adolesc Psychiatry (2014) 0.80
Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes. J Neurooncol (2013) 0.80
Cognitive development and social-emotional functioning in young foster children: a follow-up study from 2 to 3 years of age. Child Psychiatry Hum Dev (2013) 0.79
Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after 177Lu-DOTA-Tyr3-octreotate treatment: a histological study in xenografted mice. EJNMMI Res (2011) 0.79
II. In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors. J Neural Transm (Vienna) (2011) 0.79
Effects of treatment with (177)Lu-DOTA-Tyr(3)-octreotate on uptake of subsequent injection in carcinoid-bearing nude mice. Cancer Biother Radiopharm (2007) 0.79
Degraded water suppression in small volume ¹H MRS due to localised shimming. MAGMA (2011) 0.79